{'fraction_non_alphanumeric': 0.021825396825396824, 'fraction_numerical': 0.000992063492063492, 'mean_word_length': 6.207142857142857, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Oritavancin for the Treatment of Daptomycin Nonsusceptible Vancomycin-Resistant Enterococci Osteomyelitis

Abstract Vancomycin-resistant enterococci (VRE) are a growing cause of health care–associated infections globally, and limited treatment options exist for invasive VRE infections. Daptomycin is commonly used with modest success in the treatment of deep-seated infections secondary to VRE; however, there is concern for the emergence of daptomycin nonsusceptible VRE, especially during protracted courses, as required in osteomyelitis. We report the clinical and microbiologic success of a once-weekly, 6-week course of oritavancin with therapeutic drug monitoring in the treatment of daptomycin nonsusceptible VRE osteomyelitis secondary to prosthetic hip replacement. Our data suggest favorable pharmacokinetics and no treatment-related adverse events with once-weekly dosing. This report provides compelling information for future studies of prolonged oritavancin regimens in deep-seated infections.